ASX-Dividend-Report-Banner

GBI Secures Commercial Manufacturing Contract, Solidifying Leadership in Radiopharmaceutical Manufacturing

January 10, 2024 01:00 AM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 GBI Secures Commercial Manufacturing Contract, Solidifying Leadership in Radiopharmaceutical Manufacturing
Image source: Kalkine Media

PLANTATION, Fla., Jan. 9, 2024 /PRNewswire/ -- GBI BioManufacturing, formerly known as Goodwin Biotechnology, proudly announces the signing of its second Master Supply Agreement (MSA) for commercializing a radioimmunoconjugate product. This milestone not only showcases our commitment to advancing healthcare through cutting-edge radiopharmaceuticals in collaboration with our clients, but also solidifies our position as a trusted partner in the integrated CDMO biologics space, with expertise in bringing a product from clinical trials to commercial supply.

"We are thrilled to announce the signing of our second commercial contract, a testament to the exceptional capabilities and unwavering commitment of the entire GBI team," said Darrin Schellin, CEO. "This achievement highlights our expertise and experience in the radiopharmaceutical sector, and it also highlights the confidence that our clients place in us."

As the demand for radiopharmaceuticals continues to rise, GBI is positioned to meet the needs of our clients with significantly increased investments in our state-of-the-art development and manufacturing capabilities.

"We are happy to see more clients entrusting us with their long-term commercial product needs," added Karl Pinto, Chairman of the Board at GBI. "This announcement signifies the strength, longevity and strategic nature of our partnership with this fast growing, global radiopharmaceutical leader. The radiopharmaceutical space is witnessing unprecedented growth and GBI is proud to be at the forefront of this transformative industry".

About GBI

GBI is a uniquely qualified and flexible US–based CDMO (contract development and manufacturing organization) that offers a Single Source Solution to enhance the value of complex biopharmaceuticals for our clients. With over 30 years of experience as an independent contract manufacturer, GBI has worked as a strategic partner with companies and medical institutions of all sizes, taking their products through clinical trials and towards rapid commercialization. GBI provides process development and cGMP manufacturing services encompassing drug substances and drug products for complex biologics, including multi-specific antibodies, recombinant proteins, antibody- conjugates, and other biologic products.

For more information, please visit https://www.gbibio.com/
or
Contact: [email protected] 

GBI
1850 N.W. 69th Avenue
Plantation, FL 33313
Phone: 954-321-5300
Fax: 954-587-6378

Logo - https://mma.prnasia.com/media2/2312205/gbi_logo.jpg?p=medium600 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.